Share ownership Telix Pharmaceuticals Limited

TLX

AU000000TLX2

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:04 2024-09-13 am EDT			5-day change	1st Jan Change
19.05 ^AUD	+0.11%		+7.38%	+88.99%

Aug. 28	Telix Pharmaceuticals Files New Drug Application with US FDA for Brain Cancer Imaging Agent	MT
Aug. 28	Telix Submits NDA for TLX101-Cdx (Pixclara®) Brain Cancer Imaging Agent	CI

Share class: Telix Pharmaceuticals Limited

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	334,232,000	248,133,569 ( 74.24 %)	0	74.24 %

Major shareholders: Telix Pharmaceuticals Limited

Name	Equities	%	Valuation
Christian Behrenbruch 6.941 %	23,228,298	6.941 %	293 M $
Andreas Kluge 6.776 %	22,675,000	6.776 %	286 M $
Grand Pharmaceutical Group Ltd. 3.271 %	10,947,181	3.271 %	138 M $
UV-Cap Verwaltungs GmbH 2.228 %	7,454,500	2.228 %	94 M $
Oncidium Foundation 1.772 %	5,929,331	1.772 %	75 M $
State Street Bank & Trust Co. 1.179 %	3,945,039	1.179 %	50 M $
Telix Pharmaceuticals Ltd. 0.9856 %	3,298,073	0.9856 %	42 M $
Mark Nelson 0.9648 %	3,228,750	0.9648 %	41 M $
Yelwac Pty Ltd. 0.5922 %	1,981,804	0.5922 %	25 M $
Netwealth Investments Ltd. 0.5807 %	1,943,357	0.5807 %	25 M $
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Individuals	14.71%
Institutional	6.24%
Grand Pharmaceutical Group Ltd.	3.27%
Other	2.88%
Telix Pharmaceuticals Ltd.	0.99%
Unknown	71.91%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	14.71%
Australia	3.99%
Hong Kong	3.27%
Germany	2.23%
United States	1.91%
Belgium	1.77%
Ireland	0.07%
New Zealand	0.06%
United Kingdom	0.04%
France	0.04%
Mexico	0.01%

Based on 1000 largest holdings

Telix Pharmaceuticals Limited is an Australia-based is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. It operates under four business units: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech), and Telix Manufacturing Solutions (TMS). Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx.

Employees

423

Sector

Biotechnology & Medical Research

Calendar

2025-02-18 - Q4 2024 Earnings Release (Projected)

Related indices

ASX 200

More about the company